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ABSTRACT
Objective: Duchenne muscular dystrophy (DMD) is a lethal disease. The outcome measures used
in numerous therapeutic trials include skeletal muscle biopsy. We studied the natural history of
DMD from the standpoint of muscle histology with the aim of providing a reproducible tool for
use in evaluating and comparing any histologic changes occurring in patients with DMD undergo-
ing treatment and hence be able to determine how therapy modulates the histologic evolution of
the disease.
Methods: Three independent operators analyzed 56muscle biopsies from 40 patients not treated
with steroids, aged 1 to 10 years and 16 individuals treated with steroids, aged 7 to 10 years. We
analyzed morphologic measures, normalized every measure for the average number of fibers
observed for each year of age, and calculated intraclass correlation coefficients.
Results: The average proportion of connective tissue in patients not treated with steroids was
16.98% from ages 1 to 6 years and 30% from ages 7 to 10 years (p , 0.0001). The average
proportion in patients treated with steroids was 24.90%. Muscle fiber area mirrored that of
connective tissue in both groups.
Conclusions: Having provided a reproducible tool for evaluation and comparison of histologic
changes occurring in patients undergoing clinical trials, it was observed that at ages 6 to 7 years,
fibrotic tissue rapidly peaks to 29.85%; this is a crucial moment whenmuscle tissue loses its self-
regeneration ability, veering toward fibrotic degeneration. These data should be considered when
deciding the most suitable time to begin therapy. Neurology® 2015;85:1886–1893
GLOSSARY
DMD 5 Duchenne muscular dystrophy; ICC 5 intraclass correlation coefficient; MFA 5 muscle fiber area.
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in childhood,
affecting 1 in 5,000 male births.1 Currently, no resolutive treatments are available for DMD.
Glucocorticoids are considered the standard of care2; however, other approaches have been tried
and some trials are ongoing. One of the main outcome measures used in some clinical trials is
the restoration of dystrophin (e.g., ataluren, exon skipping drugs),1,3–6 while other trials focus on
modulating the cascade of morphologic events related to the lack of dystrophin (e.g., histone
deacetylase inhibitors, phosphodiesterase type 5A inhibitors, synthetic analogs of coenzyme
Q10).4,6–8 Recently, the European Medicines Agency’s Committee for Medicinal Products for
Human Use recommended conditional marketing authorization for Translarna (ataluren) for
patients with DMD and nonsense mutations in the dystrophin gene.3,4,9
In addition to clinical outcome measures, some trials include skeletal muscle biopsy as a
primary or secondary outcome measure.4 Muscle biopsy facilitates monitoring of treated
patients in terms of both dystrophin immunohistochemical expression and morphologic
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evaluation; moreover, it allows comparison of
age-matched treated and untreated patients
regarding muscle morphology in order to
determine the effects of therapy on the histo-
logic natural history of the disease. Lastly, a
systematic study of the histologic natural his-
tory of DMD is virtually absent from the lit-
erature, except for a few isolated or anecdotal
reports.10,11 We therefore studied the natural
history of DMD from the standpoint of mus-
cle histology with the aim of providing a
reproducible tool for evaluation and compari-
son of histologic changes occurring in patients
with DMD treated with steroids.
METHODS Patients. We evaluated 2 series of biopsies ob-
tained from patients with DMD, some of them treated and some
of them not treated with steroids. All patients had a diagnosis of
DMD (confirmed with genetic testing). Patients with Becker
muscular dystrophy were not included.
After considering the number and size of available samples
for each age, we decided to analyze 56 muscle biopsies
(45 brachial biceps and 11 quadriceps femoral muscles) from
40 patients not treated with steroids, aged 1 to 10 years and
from 16 individuals treated with steroids, aged 7 to 10 years.
Thus, we analyzed 4 samples for each year of age in both groups,
ensuring analytical accuracy for each selected age. We also ob-
tained muscle biopsies from 20 healthy subjects, aged 1 to 10
years (i.e., controls), who underwent orthopedic surgery for
traumatic injuries.
Standard protocol approvals, registrations, and patient
consents. All muscle biopsies were from the following: Bank of
muscle tissue, peripheral nerve tissue, DNA and cell culture of
the UODMalattie Neuromuscolari, IRCCS Ca’ Granda Ospedale
Maggiore Policlinico, Milano; Bank of cells, tissues and DNA from
patients with neuromuscular diseases, Fondazione IRCCS Istituto
Neurologico C. Besta, Milano; Laboratory of Molecular Medicine
for Muscular and Neurodegenerative Diseases, Bambino Gesù
Children’s Hospital, Rome; and Department of Neurosciences Rita
Levi Montalcini, University of Turin.
The ethical committee approved the protocol for these stud-
ies, in agreement with Italian law and Biobank rules (Telethon
Network for Genetics Biobanks and Eurobiobank).
Procedures. Muscle tissue specimens were frozen in isopentane-
cooled liquid nitrogen and the cryosections obtained were
processed according to standard histologic techniques.
Dystrophin was evaluated as described.12,13 We evaluated the
following morphologic measures: fibrotic tissue, necrotic,
regenerating and hypercontracted fibers, internal nuclei, cellular
reactions, fiber size variability, and muscle fiber area (MFA).
Three operators, each blinded to specimen type and identity,
evaluated each specimen using an optical microscope (Leica
DC200 equipped with camera and IM50 image analyzer soft-
ware) at 253 magnification for cell counting using a 0.24 3
0.24 mm square grid. Each operator observed a muscle area of
100 mm2 for each patient, choosing 4 random areas on the same
cryostatic section (12 grids for each biopsy). In each selected field,
we counted the number of necrotic, regenerating, and hypercon-
tracted fibers, as well as the number of fibers with internal nuclei
and cellular inflammatory reactions (table 1). Mean values were
calculated for all the measures for each age (4 biopsies analyzed for
each age). The final value represents the mean of the mean values
obtained by each operator. Values were expressed as a percentage
of the total number of fibers in each microscopic grid field. We
used intraclass correlation coefficients (ICCs) to assess the relia-
bility of each morphologic measure and the agreement between
operators14 (table 2).
For evaluation of fiber size variability, we used a scale rang-
ing from 1 (minimal variability of fiber size) to 11111
(greatest variability), as described in an earlier article.15 To
quantify the extent of fibrotic tissue, i.e., the quantity of both
perimysial and endomysial tissue, we analyzed 4 digitized non-
overlapping consecutive images for each biopsy section using an
optical microscope (Leica DC200) at 253 magnification
with IM50 software. Then we processed the images with
ImageJ 1.46r (NIH, downloadable at http://rsbweb.nih.gov/
ij/download.html) to obtain measurements of total fibrosis by
color subtraction, which were then expressed in percentage area,
as described previously (figure 1).16 ImageJ is a widely available,
free image analysis software used to measure tissue areas and
Table 1 Comparison of the morphologic measures in patients not treated vs treated with steroids, aged 7 to
10 years
Age at biopsy, y
7 8 9 10
Steroid therapy No Yes No Yes No Yes No Yes
Necrotic fibers 1.61 2.52 1.59 2.30 1.67 3.16 1.81 2.16
Regenerating fibers 0.80 1.01 2.60 0.74 1.96 1.34 0.42 1.05
Internal nuclei 5.01 5.19 8.65 7.35 6.02 6.31 8.90 6.32
Hypercontracted fibers 0.72 0.75 0.57 0.25 1.72 0.57 0.69 0.38
Cellular reactions 0.09 0.09 0.05 0.17 0.28 0.37 0.32 0.00
Fiber size variabilitya 111 111 111/1111 111 1111 111 1111 1111
Connective tissue 29.76 24.82 32.75 22.56 27.42 29.85 29.98 22.38
Muscle fiber area 69.84 72.83 66.02 77.09 71.64 68.44 74.47 76.11
Data are percentages.
a For fiber size variability, we used a scale ranging from 1 (minimal variability of fiber size) to 11111 (greatest variability).
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volumes with highly reliable results.17,18 MFA is the area occu-
pied by normal, nonnecrotic muscular tissue. To calculate the
percentage of MFA, the same images were analyzed, with the
same ImageJ software, to quantify the area occupied by necrotic
fibers. Then, the percentage of necrotic and fibrotic tissue was
subtracted from the total area of each image. Average MFA
values were calculated for each patient and each age. Student
t test was used for data analysis.
RESULTS Control muscle samples. All specimens had
normal muscle architecture with homogeneous
fiber size, no necrotic muscle fibers, and less than
2% internalized nuclei and/or splitting fibers. We
did not detect any regenerative fibers. The percent-
age of connective tissue was 3% or less in every
patient, and fiber size variability was normally
related to fiber type. Dystrophin was normally
localized at the sarcolemma.
DMD muscle samples. We detected no morphologic
differences between biceps and quadriceps muscles
for any of the analyzed measures. All samples showed
variable, but increased perimysial and endomysial
connective tissue, frequent fibrotic substitution of
single fibers and/or entire fascicles, and several prene-
crotic (hyperchromic/hypercontracted) and several
necrotic fibers, the latter sometimes with macro-
phagic infiltrations. Dystrophin was absent in all
specimens. Scattered revertant fibers were detected
in a few specimens in a range from 0.02% to 6% in
agreement with the usual representation of revertant
fibers seen in the DMD population.19–21 No correla-
tions between presence of revertant fibers, clinical
severity, and disease progression have been reported
so far.22,23 We observed regenerative fibers, often
located in small groups, splitting fibers, centrally
located nuclei, and also fiber size variability due to
the presence of both hypertrophic and hypotrophic
fibers. The alterations described were present in all
specimens, sometimes with major quantitative differ-
ences depending on patient age.
Patients not treated with steroids (40 patients). Connective
tissue. We observed increased connective tissue, up to
16.50% (SD 7.84) as early as 1 year of age (3% in
healthy patients of the same age), which increased on-
ly slightly until the age of 6 years. However, we
observed a more consistent and rapid increase in
Table 2 Intraclass correlation coefficients
ICC (95% CI)
Necrotic fibers 0.85 (0.80–0.90)
Cellular reactions 0.35 (0.22–0.50)
Internal nuclei 0.83 (0.76–0.88)
Hypercontracted fibers 0.71 (0.61–0.79)
Regenerations 0.69 (0.59–0.78)
Abbreviations: CI 5 confidence interval; ICC 5 intraclass
correlation coefficient.
Coefficient values of #0.20 indicate poor agreement;
0.21–0.40, fair agreement; 0.41–0.60, moderate or
acceptable agreement; 0.61–0.80, substantial agreement,
and 0.81–1.0, almost perfect agreement.
Figure 1 Connective tissue assessment (perimysial and endomysial)
(A and C) Hematoxylin & eosin staining. (B and D) Color subtraction of A and C using ImageJ 1.46r software to measure total
fibrosis. Leica DC200 optical microscope, 253 magnification.
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fibrotic tissue between 6 and 7 years of age. Indeed,
at age 7 years, the proportion rises to 29.85% (SD
7.75), an increase of more than 10% in only 1 year.
Between the ages of 7 and 10 years, the increase
resumed a slowly progressive trend (figure 2).
Thus, our cohort can be separated into 2 groups
corresponding to 2 age ranges: 1–6 years and 7–10
years. Average connective tissue percentages were
16.98% (SD 4.90) and 30% (SD 8.65), respec-
tively (p , 0.0001).
Necrotic fibers. The percentage of necrotic fibers
rapidly increased from 1 to 3 years of age (from
0.38% [SD 0.26] to 2.95% [SD 2.11]) then the val-
ues remained quite stable (range: 1.51% [SD 1.28]
and 1.81% [SD 0.61]) except for a slight reduction
at the age of 6 years (0.93% [SD 0.63]).
Regenerative fibers.We observed a mildly progressive
increase in regenerative fibers between 1 and 6 years
(0.56% [SD 0.37] to 1.36% [SD 1.6]) and between
8 and 9 years of age (2.6% [SD1.86] and 1.96%
[SD 1.58]), a decreasing trend being evident at 7
(0.8% [SD 0.3]) and 10 years of age (0.42% [SD
0.37]). For fibers with central nuclei, we observed a
progressive increase in their number from 1.31%
(SD 0.64) to 8.90% (SD 3) between 1 and 10 years
of age. The percentage of hypercontracted fibers was
quite low and stable for all ages.
Conversely, cellular infiltrates were scattered, in
small amounts, in some samples without any observ-
able correlation with age and/or number of necrotic
fibers (figure 3).
MFA.MFA values remained quite stable between
1 and 6 years of age (range: 79.14% [SD 0.05] to
85.04% [SD 0.06]), then we observed a reduction
in patients older than 7 years (range: 69.84%
[SD 0.1] to 74.47% [SD 0.05]). The average
MFA percentage for ages 1–6 years and ages 7–10
years was 82.3% (SD 2.26) and 70.49% (SD 3.54),
respectively (p , 0.0001) (figure 2). Fiber size var-
iability increased progressively with age.
Figure 2 Connective tissue and MFA evaluation in untreated and treated patients
(A) Connective tissue in patients not treated with steroids (40 patients) shows a more consistent and rapid increase in fibrotic
tissue between6 and7 years of age. At the age of 7, the proportion rises to 29.85% (SD7.75) corresponding to an increase of
more than 10% in 1 year. Connective tissue in patients treated with steroids (16 patients aged 7–10 years) ranged from
22.38% (SD 8.5) to 29.85% (SD 6.49) with increasing age. (B) MFA in the steroid-free group (40 patients). The values
remained quite stable between 1 and 6 years of age (range from 79.14% [SD 0.05] to 85.04% [SD 0.06]), but a reduction
was evident in patients older than 7 years (values between 69.84% [SD 0.1] and 74.47% [SD 0.05]). In the steroid-treated
group (16 patients aged 7–10 years), MFA values ranged between 68.44% (SD 0.08) and 77.09% (SD 0.13).
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Steroid-treated group (16 patients). The amount of con-
nective tissue increased with age, between 22.38%
(SD 8.5) and 29.85% (SD 6.49) (figure 2), whereas
necrotic fibers were quite stable for all ages examined
(range: 2.16% [SD 1.06] to 3.16% [SD 2.44]). MFA
values ranged between 68.44% (SD 0.08) and
77.09% (SD 0.13) (figure 2).
Regenerative fibers remained quite stable, between
0.74% (SD 0.68) and 1.34% (SD 2.45) for all ages
examined.
The percentage of fibers with internal nuclei
increased from 5.19% (SD 1.31) at age 6 years to
7.35% (SD 5.66) at age 7 years, and a slight reduc-
tion was observed at the ages of 9 and 10 years
(6.43% [SD 3.80] to 6.32% [SD 2.27]).
We observed a 0.25% (SD 0.22) to 0.75% (SD
1.23) proportion of hypercontracted fibers, whereas
inflammatory cell reactions remained below 0.37%
(SD 0.25) in all the ages examined (figure 3). Fiber
size variability increased with age.
The ICC index showed a medium to high agree-
ment for all examined measures, except for the
inflammatory reaction in which the ICC test was
compromised because of the extremely low number
of infiltrates per biopsy (table 2).
DISCUSSION We studied the evolution of muscle al-
terations in a large cohort of both steroid-treated and
untreated patients with DMD to characterize the
human histologic natural history model of DMD.
Figure 3 Evaluation of morphologic measures in patients without and with steroids
(A) Necrotic fibers, regenerating fibers, internal nuclei, hypercontracted fibers, and cellular reactions in patients not treated with steroids (40 patients). (B)
Necrotic fibers, regenerating fibers, internal nuclei, hypercontracted fibers, and cellular reactions in patients treated with steroids (16 patients).
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We focused on the age-related changes in several
morphologic measures. To reduce possible errors
caused by interindividual variability, we analyzed 4
patients for each year of age and validated the results
using the ICC.
Our most interesting result is quantification of
connective tissue in the patient samples. Previous re-
ports10 distinguished between perimysial and endo-
mysial tissue. We considered connective tissue as a
whole, because both perimysium and endomysium
contribute to the formation and maintenance of the
normal muscle environment.16 The steroid-free group
of muscle biopsies had increasing connective tissue as
early as age 1 year (16.50%) compared with healthy
control subjects (3%), dating the beginning of skele-
tal muscle degeneration back to intrauterine life.24,25
The amount of connective tissue—expressing the
fibrotic substitution of muscle tissue—remains stable
until 6 years of age (13.94%–19.47%), probably
because muscle homeostasis is still able to support
the rapid degenerative–regenerative turnover until
that age.26–30 Between 6 and 7 years of age, fibrotic
tissue rapidly peaks to 29.85% (more than a 10%
increase), then it resumes a mild but progressive
increase (27.42%–32.75%) until the age of 10 years.
Grouping our samples in 2 age ranges, the first from
1 to 6 and the second from 7 to 10 years of age, we
calculated an average connective tissue amount of
16.65% (SD 1.59) for the former and 30% (SD
2.18) for the latter. These data correlate with MFA
values: we observed that the average percentage of
muscular tissue for ages 1–6 years and 7–10 years
was 82.07% and 70.26%, respectively. Our findings
point to the age of 6–7 years as a crucial time period
in which muscle tissue loses the ability to self-
regenerate, veering toward fibrotic degeneration. In
view of these results, it is probably no coincidence
that patients undergoing steroid treatment, usually
starting at age 5 years (in our group between 5 and
6 years of age), show lower amounts of connective
tissue and higher MFA values when compared to
aged-matched patients not treated with steroids (table
1 and figure 2). Indeed, even though connective
tissue is seen to increase even in patients treated with
steroids, it is still reasonable to think that fibrotic
degeneration is slowed down by the treatment, which
would account for the clinical improvements
observed.31,32
For necrotic fibers, our results are in agreement
with previous studies reporting no significant trends
during the evolution of the disease.10 It should be
noted that patients treated with steroids had a greater
proportion of necrotic fibers. We believe that the
increase in necrotic component may be due to the
suppression of inflammatory response by the steroids,
which somehow preserves the necrotic fibers and
modifies the muscular environment also linked to
cytokine production.26–30
Regenerating fibers are interesting to analyze
because these fibers are central to the muscle repair
process. Our results show a progressively increasing
quantity of regenerating fibers from 1 to 6 years of
age (0.56%–1.36%) followed by a variable trend
from 7 to 10 years of age (figure 3). We observed a
substantially stable number of regenerating fibers in
patients treated with steroids. In the 2 groups, the
amount of necrotic fibers was always higher compared
to regenerating fibers (according to age groups), as
expected (table 1 and figure 3).
The percentage of fibers with central nuclei (i.e.,
muscle cells that had previously undergone a regener-
ative process) progressively increased with age, show-
ing no differences between treated and untreated
patients.
Hypercontracted fibers and cellular infiltrates did
not correlate to age in either DMD group (table
1 and figure 3). This is not in agreement with previ-
ous studies, which showed a higher number of hyper-
contracted fibers at younger ages.10
We were able to make some correlations between
morphologic and clinical disease evolution in the first
decade of life, but we must consider that even though
the clinical progression is well known,33 the morpho-
logic evolution history is still not well elucidated.
It is not easy to recognize DMD in the first 2 years
of life because the only clues are nonspecific preclin-
ical signs such as a lower position on the growth
curve.34 Indeed, more consistent and almost pathog-
nomonic symptoms such as gait abnormalities and/or
difficulties in climbing stairs and running only
become evident around the age of 3 years. Between
3 and 6 years of age, almost all patients develop a
hyperlordotic and waddling gait, Gower sign, scapu-
lar winging, hypertrophic calves, and contractures.
Six-Minute Walk Test distance starts to decrease
around 7 years of age.35
Respiratory impairment usually starts at approxi-
mately 8 to 9 years of age and ambulation ability is
lost at around the age of 13 years.33 Creatine kinase
levels are already increased in the first year of life and
progressively increase until the age of 6 years, at
which time the levels start to decrease because of pro-
gressive muscle consumption.36
Clinical and laboratory data correlate with our
morphologic observations and confirm that, around
the age of 6 to 7 years, the well-known dramatic pro-
gression of weakness is mainly activated due to irre-
versible fibrotic muscle degeneration along with
other epigenetic factors still under identification. As
observed, when started before this crucial point is
reached, steroid treatment helps delay the loss of
motor skills.
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Identification of a crucial moment for muscle tissue
preservation is essential to establish the most correct
recruitment age for participation in clinical trials.
Indeed, we recommend considering the age of 6 years
as a cutoff point and recommend starting treatment
before skeletal muscle loses the ability to self-
regenerate and shifts toward fibrotic degeneration. Elu-
cidating what causes this sudden, unexpected change
in muscle homeostasis is beyond the scope of this
study. Investigators should consider exploring the pos-
sible role of epigenetic pathways regulating muscle
homeostasis, which may involve various cytokines, as
well as growth factors and differentiation factors.26–30,37
Our data regarding quantification of connective
tissue in patients treated with steroids aged 6 to 10
years could be used as a morphologic measure for
evaluation of the therapeutic efficacy in clinical trials
using morphologic evaluation as an outcome mea-
sure. It is hoped that comparisons between connec-
tive tissue amount trends in treated patients and
our data will shed more light on treatment efficacy.
This study is based on a cross-sectional retrospec-
tive design; a longitudinal study design would have
been a better model to conduct the analyses on a
larger patient cohort. However, the main drawback
to a longitudinal study is of an ethical nature, since
it would imply performing repeated muscle biopsies
on the same child.
Muscle MRI is a developing tool, and even though
it gives no information about the evolution/progression
of certain morphologic measures (number of necrotic
or hypercontracted fibers, exact localization of connec-
tive tissue inside the muscular fascicles), we anticipate
that it will permit the longitudinal assessment of muscle
tissue to be performed without the need for invasive
procedures.38,39 We believe that MRI and muscle biop-
sies can be complementary for the definition of pro-
gressive muscle alterations over time.
We think that this morphologic model for the sys-
tematic study of DMD skeletal muscle is a useful tool
to help define the correct recruitment age for clinical
trials and facilitate the interpretation of the results of
current and previous studies by comparing the post-
therapy conditions of the muscles with those pre-
dicted by the natural histologic history of the disease.
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